Normunity

Biotechnology company creating a new class of precision immuno-oncology medicines called immune normalizers that free the body’s normal immunity against cancer.

[Normunity @normunity]

Today is #AdministrativeProfessionalsDay, and the Normunity team is sending a special thank you to Suzanne, who keeps us all on track as a stellar contributor to our success and progress in our fight against cancer.

[Normunity @normunity]

Today we announced a multi-program collaboration that leverages Alloy’s high-velocity antibody discovery offering to accelerate Normunity’s novel precision #ImmunoOncology pipeline. #ImmuneNormalizers
https://t.co/HVN7W3eBuJ

[Normunity @normunity]

Christina Cho, PhD, Rachel Humphrey, CEO, and Melinda Merchant, SVP Clinical Development enjoying the sessions at SITC #SITC2022

[Normunity @normunity]

Normunity was well represented at SITC Friday night by our very own CEO Rachel Humphrey who was on stage with the Checkpoints Band! #SITC2022 #Checkpoints

[Ben Fidler @BentheFidler]

With new #startup, immunotherapy pioneer Lieping Chen tries to turn ‘cold’ tumors ‘hot’ https://t.co/VPHxcz5rEp $NXTC $AZN $BMY $MRK

[Endpoints News @endpts]

Normunity, which combines the words normal and immunity, is launching out of stealth with a $65 million Series A. The 15-month-old West Haven and Boston-based biotech wants to address T cell exclusion, or when T cells can’t get into tumors.

https://t.co/USWWMDL6R7

[Normunity @normunity]

Congratulations to the Normunity team for today’s exciting launch. Looking forward to great things and #ImmuneNormalizers to come. #NormunityAgainstCancer

https://t.co/six3jYfq1b

[Normunity @normunity]

Normunity has launched with 1) a powerful premise to reach novel I-O targets to free normal immunity, 2) a unique R&D model working with the Lieping Chen lab and 3) strong momentum to advance life-changing medicines for patients. #NormunityAgainstCancer
https://t.co/six3jYfq1b

[Normunity @normunity]

We’re thrilled to unveil Normunity to the biotech world. @bostonglobe @RLCscienceboss explores our revolutionary approach to novel cancer immunotherapies that free the normal immune system to fight cancer.
#NormunityAgainstCancer

https://t.co/acUe9RCzLU

[Normunity @normunity]

Normunity’s pipeline of novel cancer immunotherapies is drawn from the ongoing & interactive academic-biotech research leveraging proprietary discovery platforms from the lab of Dr. Lieping Chen at Yale School of Medicine.
#NormunityAgainstCancer
https://t.co/six3jYxzfj

[Normunity @normunity]

Normunity announces $65 million Series A to expand the frontier of precision immuno-oncology with immune normalizer therapies. Our medicines target unprecedented mechanisms that free the body’s normal immunity against cancer.
#NormunityAgainstCancer
https://t.co/KTKa2lhlkz

[Normunity @normunity]

Introducing Normunity, opening new frontiers in immuno-oncology. We reveal hidden mechanisms to free the immune system to work normally against cancer. These are novel targets for our new class of #ImmuneNormalizers to cure cancer. #ImmunoOncology
https://t.co/six3jYfq1b